Topotecan in Platinum-Resistant Epithelial Ovarian Cancer

Abstract

Background: Topotecan has been emerged as a new promising anticancer drug for patients with ovarian cancer. Methods: In this study, patients who were treated with topotecan were reviewed retrospectively. A total of 26 patients was included the study. All patients had received platinum-based regimens previously. Topotecan was administered a dose of 1.5 mg/m² intravenously 30 min daily for 5 days and repeated every 21 days. Results: The response rates were 30% by CA-125 level and 29% in clinic evaluation. Median duration of response was 8 (3–15) months, median progression-free interval was 12 (4–30) months and median overall survival was 15 (4–36) months. Grade 3–4 neutropenia occurred in 58% of the patients (38% of the courses) and trombocytopenia in 29% of the patients (12% of the courses). Nonhematological toxicities were mild. There was no drug-related death. Conclusion: Topotecan is considered as a reasonable option for treatment of patients with platinum refractory recurrent ovarian cancer.

A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer

“…PLD and topotecan are FDA-approved chemotherapies for recurrent ovarian cancer [5,19]. Since trebananib blocks unique molecular targets, the addition of trebananib to PLD or topotecan was expected to improve efficacy without exacerbating known toxicities associated with PLD or topotecan monotherapy.…”

Targeted Therapies in Platinum-Resistant Ovarian Cancer: Advances in Immunotherapy Combination Strategies

“…In many cases, initial recurrences are platinum-sensitive but the disease eventually becomes platinum-resistant; which is defined as disease progressing within 6 months of platinumbased therapy [4,5]. Platinum-resistant patients are subsequently limited to non-platinum and non-taxane chemotherapy treatment options such as topotecan, gemcitabine, and pegylated liposomal doxorubicin which have shown moderate therapeutic success [6]. Alternative treatment options for platinum-resistant disease are, therefore, constantly being explored and immunotherapy and targeted agents are increasingly undergoing clinical trials which are showing positive results.…”

A Phase I Trial of High-Dose Chemotherapy Combining Topotecan plus Cyclophosphamide with Hematopoietic Stem Cell Transplantation for Ovarian Cancer: The ITOV 01bis Study

“…Topotecan, a topoisomerase I inhibitor, is a commonly used agent for relapsed ovarian cancer, but its use carries myelosuppression as a major toxicity [2,22,23]. However, in the context of transplantation this is no longer considered as a dose-limiting factor [24].…”